59 results
6-K
EX-99.1
GLPG
Galapagos NV
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
in the future, and the risks and uncertainties relating to the impact of the COVID-19 pandemic. A further discussion of these risks, uncertainties and other risks
6-K
EX-99.2
GLPG
Galapagos NV
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
and uncertainties related to the impact of the COVID-19 pandemic. A further list and description of these risks, uncertainties and other risks can be found
6-K
EX-99.1
GLPG
Galapagos NV
25 May 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
5:49pm
pandemic, as well as those risks and uncertainties identified in our most recent Annual Report on Form 20-F filed with the U.S. Securities
6-K
EX-99.1
GLPG
Galapagos NV
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
to the impact of the COVID-19 pandemic. A further discussion of these risks, uncertainties and other risks can be found in our filings and reports
6-K
EX-99.1
GLPG
Galapagos NV
2 May 23
Current report (foreign)
4:15pm
to execute on our currently contemplated business plan and/or will need to revise our business plan, and risks related to the COVID-19 pandemic
6-K
EX-99.1
so6p aeyahoix8gvlytm
31 Mar 23
Current report (foreign)
6:05am
6-K
EX-99.1
1qd2l4oc9qga2g5cdv
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
6-K
EX-99.1
4bgb5 h88
14 Nov 22
Current report (foreign)
6:05am
6-K
EX-99.1
hob1rukk1bzekd4eusdz
9 Nov 22
Current report (foreign)
4:05pm
6-K
EX-99.1
j0z4y5n
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
pvo7k z0z
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
obmjle0wn5ru3ugpbu
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm
6-K
EX-99.1
rehe4irv85z0egv6c
6 Oct 22
Current report (foreign)
5:11pm
6-K
EX-99.1
5cufx r2pkszhz
3 Oct 22
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
6:02pm
6-K
EX-99.1
nymqeiqa 5v
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.2
d5drsagf7gwrsx7y4
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.1
2i2grcjfl
23 Jun 22
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
11:21am
6-K
EX-99.1
fe407npo3d6rm1bsw
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.2
p4ry0ki5
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.2
or0 crlupk0husmh
11 Apr 22
Current report (foreign)
5:14pm